The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), Boehringer Ingelheim and Eli Lilly and Company announced.
- Read more about CHMP issues positive opinion for Jardiance for the treatment of heart failure
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/chmp-issues-positive-opinion-for-jardiance-empagliflozin-for-the-treatment-of-adults-with-heart-failure-with-reduced-ejection-fraction
No comments:
Post a Comment